Limits...
Male breast cancer: 10-year experience at mansoura university hospital in egypt.

El-Beshbeshi W, Abo-Elnaga EM - Cancer Biol Med (2012)

Bottom Line: OS was not significantly affected by any of the studied parameters.MBC is a rare disease and often diagnosed at a locally advanced stage.The management of male and female breast carcinoma is identical.

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Mansoura University, Mansoura, El-Daklalia 002, Egypt.

ABSTRACT

Objective: Male breast cancer (MBC) is a rare disease representing less than 1% of all malignancies. The objective of the study is to report clinicopathological characteristics, treatment patterns, and outcomes of MBC in Mansoura University Hospital, Egypt.

Methods: This retrospective study focused on male breast cancer patients during 10 years (2000-2009). The studied variables were data regarding general characteristics of patients, treatment modalities and survival.

Results: The series included 37 patients (0.8% of all breast cancer). The median age was 57.7 years (range: 26-86 years). The main clinical complaint was a mass beneath the areola in 94.5% of the cases. Most patients had a locally advanced disease. 94.5% of tumors were invasive duct carcinomas. The treatment was essentially surgery in 91.8%, followed by adjuvant radiotherapy (in 89.2%), hormonal therapy (in 56.7%) and chemotherapy (in 91.8%). Follow-up period ranged from 6-115 months. Local recurrence occurred in 4 cases and metastasis in 11 cases. The 2-year and 5-year overall survival (OS) rates were 81.6% and 60.5%, respectively. The 2-year and 5-year disease-free survival (DFS) rates were 68.4%, and 52.6%, respectively. OS was not significantly affected by any of the studied parameters. Factors influencing DFS were: T stage (P=0.05), positive lymph nodes (P=0.043), metastasis (P=0.004), and chemotherapy (P=0.046).

Conclusions: MBC is a rare disease and often diagnosed at a locally advanced stage. The management of male and female breast carcinoma is identical. Future research for better understanding of this disease is needed to improve the management and prognosis of male breast cancer patients.

No MeSH data available.


Related in: MedlinePlus

Overall survival.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3643641&req=5

f1: Overall survival.

Mentions: The 2- and 5-year OS rates were 81.6% and 60.5%, respectively. The median OS time was 63 months (mean: 49.9 months) (Figure 1). The 2- and 5-year DFS rates were 68.4%, and 52.6%, respectively. The median DFS time was 62 months (mean: 43.7 months) (Figure 2).


Male breast cancer: 10-year experience at mansoura university hospital in egypt.

El-Beshbeshi W, Abo-Elnaga EM - Cancer Biol Med (2012)

Overall survival.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3643641&req=5

f1: Overall survival.
Mentions: The 2- and 5-year OS rates were 81.6% and 60.5%, respectively. The median OS time was 63 months (mean: 49.9 months) (Figure 1). The 2- and 5-year DFS rates were 68.4%, and 52.6%, respectively. The median DFS time was 62 months (mean: 43.7 months) (Figure 2).

Bottom Line: OS was not significantly affected by any of the studied parameters.MBC is a rare disease and often diagnosed at a locally advanced stage.The management of male and female breast carcinoma is identical.

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Mansoura University, Mansoura, El-Daklalia 002, Egypt.

ABSTRACT

Objective: Male breast cancer (MBC) is a rare disease representing less than 1% of all malignancies. The objective of the study is to report clinicopathological characteristics, treatment patterns, and outcomes of MBC in Mansoura University Hospital, Egypt.

Methods: This retrospective study focused on male breast cancer patients during 10 years (2000-2009). The studied variables were data regarding general characteristics of patients, treatment modalities and survival.

Results: The series included 37 patients (0.8% of all breast cancer). The median age was 57.7 years (range: 26-86 years). The main clinical complaint was a mass beneath the areola in 94.5% of the cases. Most patients had a locally advanced disease. 94.5% of tumors were invasive duct carcinomas. The treatment was essentially surgery in 91.8%, followed by adjuvant radiotherapy (in 89.2%), hormonal therapy (in 56.7%) and chemotherapy (in 91.8%). Follow-up period ranged from 6-115 months. Local recurrence occurred in 4 cases and metastasis in 11 cases. The 2-year and 5-year overall survival (OS) rates were 81.6% and 60.5%, respectively. The 2-year and 5-year disease-free survival (DFS) rates were 68.4%, and 52.6%, respectively. OS was not significantly affected by any of the studied parameters. Factors influencing DFS were: T stage (P=0.05), positive lymph nodes (P=0.043), metastasis (P=0.004), and chemotherapy (P=0.046).

Conclusions: MBC is a rare disease and often diagnosed at a locally advanced stage. The management of male and female breast carcinoma is identical. Future research for better understanding of this disease is needed to improve the management and prognosis of male breast cancer patients.

No MeSH data available.


Related in: MedlinePlus